PTPA and chronic myelogenous leukemia, BCR-ABL1 positive: Lai et al., reporting data on PIDs (PP2A-inhibiting drugs) such as LB100 (or the lipid-soluble LB102), have recently reconsidered this view on PP2A role in CML.